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Abstract 
Background: The spread of Plasmodium falciparum resistance to artemisinin derivatives in Southeast Asia is a major 
source of concern and the emergence of resistance in Africa would have dramatic consequences, by increasing 
malaria mortality and morbidity. It is therefore urgent to implement regular monitoring in sentinel sites in sub‑Saha‑
ran Africa using robust and easy‑to‑implement tools. The prevalence of k13‑propeller mutations and the phenotypic 
profiles are poorly known in sub‑Saharan Africa. Here, the k13‑propeller polymorphism was compared to both ex vivo 
susceptibility to DHA and early parasitological and clinical responses to artemisinin combination therapy (ACT).
Methods: Plasmodium falciparum isolates were collected in 2015 in Yaoundé (Cameroon) from patients treated with dihy‑
droartemisinin‑piperaquine combination. Samples were analysed for their susceptibility to artemisinin using the k13‑propel‑
ler sequencing, the ex vivo ring‑stage survival assay, the in vivo parasite positive rate and the clinical statute at day 2.
Results: None of the collected isolates revealed the presence of resistance mutations in the k13‑propeller sequence. 
The median ring‑stage survival rate for all the 64 interpretable isolates after a 6‑hour pulse of 700 nM dihydroarte‑
misinin was low, 0.49% (IQR: 0–1.3). Total parasite clearance was observed for 87.5% of patients and the remaining 
parasitaemic isolates (12.5%) showed a high reduction of parasite load, ranging from 97.5 to 99.9%. Clinical symptoms 
disappeared in 92.8% of cases.
Conclusion: This study demonstrated the absence of k13‑resistant genotypes in P. falciparum isolates from Cam‑
eroon. Only synonymous mutations were found with a low prevalence (4.3%). A good association between k13 geno‑
types and the ex vivo ring‑stage survival assay or parasitological and clinical data was obtained. These results give a 
baseline for the long‑term monitoring of artemisinin derivative efficacy in Africa.
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Background
Malaria remains a major public health problem largely 
due to Plasmodium falciparum drug resistance. Arte-
misinin (ART)-based combination therapy (ACT) is the 
first-line treatment for falciparum malaria, used world-
wide to ensure the highest cure rates and to reduce the 
spread of drug resistance [1]. Unfortunately ART-resist-
ant P. falciparum was reported on the Cambodia/Thai-
land border in 2008, characterized by a reduced parasite 
clearance in patients as primary parasitological feature 
[2]. ART-resistance has spread and today the resist-
ance has been confirmed in five countries of the Greater 
Mekong Sub-region [3–7]. The identification of ART 
resistance in Asia is reminiscent of previously emerged 
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resistance to chloroquine and sulfadoxine-pyrimeth-
amine, which appeared in the same region and rather 
quickly reached Africa with dramatic consequences of 
increased malaria mortality and morbidity [8, 9]. The 
only question for Africa is to know when and where 
resistance to artemisinins will appear. It is, therefore, 
urgent to implement regular monitoring in several senti-
nel sites in sub-Saharan Africa using robust and easy-to-
implement tools.
In the presence of ART derivatives, resistant parasites 
are able to stop their life cycle in ring stage and enter in 
quiescence [10–12]. Because of this particular mecha-
nism of resistance, different from other anti-malarials, the 
standard determination of 50% inhibitory concentration 
(IC50) is not informative for assessing the level of resist-
ance of P. falciparum isolates to ART derivatives. Today, 
in addition to clinical trials, two new tools are available for 
surveillance of ART resistance: (i) the detection of single 
nucleotide polymorphisms (SNPs) in the PF3D7_1343700 
kelch propeller (k13-propeller domain) that have been 
identified as a key causal determinant in Southeast Asia 
[13, 14]; and, (ii) the ring-stage survival assay (RSA) [15] 
that gives phenotypic information, evaluating by micro-
scopic counting the proportion of viable parasites after a 
6-hour exposure to 700 nM dihydroartemisinin (DHA).
A total of 186 different k13 alleles have been reported 
[16] in Southeast Asia so far. In Africa, different non-
synonymous k13-propeller-region mutations have been 
reported but remain rare and highly diverse [17–19]. 
Moreover, these SNPs were different from those in Asia 
and have never been associated with increased parasite 
half-life values or clinical failures [19–22]. So the moni-
toring of ART susceptibility must be implemented in 
Africa but it will require the establishment of a baseline 
correlation between genotypic and phenotypic data. Fur-
thermore, to date only one study performed in Uganda 
evaluated the ex  vivo RSA associated with k13 polymor-
phism on few isolates (n  =  43), and this study did not 
report any increased survival rate associated with non-
synonymous k13 mutation [17].
In this work, the polymorphism in the k13-propeller 
domain of P. falciparum isolates from Yaoundé, Cam-
eroon was evaluated and these genotypic data were asso-
ciated to the in vivo and ex vivo phenotypic results. Thus, 
all these results provided baseline data of survival rate 
profiles according to the k13 gene polymorphism of Afri-
can P. falciparum isolates.
Methods
Study site and design
A prospective study was carried out between March and 
June 2015 in the Nkol-Eton healthcare centre in Yaoundé 
intra-muros, Cameroon. A finger-prick, Giemsa-stained, 
thick smear was performed on all patients with symp-
toms of malaria to assess the presence of P. falciparum 
asexual parasites. Patients ≥4 years old, with uncompli-
cated falciparum malaria and >1000 asexual parasites per 
μl on positive thick blood smear, were enrolled as volun-
teers after they or their parents had signed an informed 
consent form. Patients who had any anti-malarial treat-
ment within the 15-day period before falciparum diag-
nosis were excluded from the study. Patients with severe 
malaria (defined by WHO criteria) or with vomiting pre-
venting any oral treatment were referred to the hospital 
for adequate care and were not included in the study. At 
enrolment (day 0), study subjects’ parasite density, body 
temperature and body weight were recorded along with 
any other symptoms and signs.
The patients enrolled in the study were given a three-
day course of DHA 40  mg/piperaquine (PPQ) 320  mg 
(Malacur®, Elder Pharmaceuticals LTD, India) according 
to recommendations. The prescription was based on body 
weight (10 to <20 kg: 40 mg DHA + 320 mg PPQ or one 
tablet; 20 to <40 kg: 80 mg DHA + 640 mg PPQ or two 
tablets; ≥40 kg: 120 mg DHA + 960 mg PPQ or three tab-
lets). To ensure good treatment compliance the patients 
took the first dose of DHA/PPQ in Nkol-Eton healthcare 
centre in presence of a nurse and went home with the sec-
ond dose. Twenty-four hours after enrolment, a phone call 
to patients ensured that the second dose was well taken. 
The last third dose of DHA/PPQ was given during the 
follow-up visit on day 2 at the Nkol-Eton healthcare cen-
tre in presence of a nurse. In case of treatment failure, a 
standard replacement anti-malarial therapy (quinine salts) 
was administered according to WHO recommendations.
Ethics statement
All procedures involving human subjects used in this 
study were approved by the Cameroonian National Ethi-
cal Committee (statement n°: 2015/04/582/CE/CNERSH/
SP).
Ex‑vivo ring‑stage survival assay (RSA)
Venous blood samples were collected into acid-citrate-
dextrose (ACD) vacutainers at day 0 before treatment, and 
were kept at 4  °C until processing. The ex  vivo RSA was 
performed directly from the ACD blood sample within 
24  h after blood collection, as previously described [15]. 
Briefly, after elimination of plasma, white cells and anti-
coagulant, P. falciparum parasites with a parasitaemia 
between 0.1 and 1% were exposed to either 700 nM DHA 
or 0.1% dimethyl sulfoxide (DMSO) (DHA solvent) for 
6 hours, washed and then cultivated for 66 h at 37 °C under 
humid, oxygen-deficient atmosphere (candle jar). Micro-
scopic quantification of the proportion of viable parasites 
was performed by expert microscopists on Giemsa-stained 
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thin smears to calculate the growth rate as the ratio of par-
asitaemia between DMSO-exposed and initial conditions, 
and the survival rate as the ratio of parasitaemia between 
DHA-exposed and DMSO-exposed conditions. Survival 
data were considered interpretable only if the growth 
rate was ≥1. Equipment necessary for implementation of 
RSA included laminar flow hood, candle jar (without gas), 
−20 °C freezer, 4 °C fridge, and cold chain.
Sequencing of k13‑propeller domain
DNA was extracted from venous blood samples obtained 
at patient enrolment (day 0) using the spin protocol of 
QIAamp Mini kit® (Qiagen, Hilden, Germany) accord-
ing to manufacturer’s recommendations. PCR ampli-
fication and sequencing of k13-propeller domain were 
performed, as previously described [13]. After control on 
1.5% agarose gel electrophoresis, the PCR products were 
sequenced by ABI 3130xl Genetic Analyzer. Sequences 
were compared to 3D7 reference strain sequence with 
BioEdit Sequence Alignment Editor (version 7.2.3).
Early clinical and parasitological responses to treatment
Patients were asked to return to the healthcare centre 
for follow-up visits on day 2 after treatment. Each visit 
included completion of a standardized history form, a 
physical/clinical examination for recording any signs 
(temperature) or symptoms (headache, vomiting, diar-
rhoea, diffuse pain), and a finger-prick blood sample for 
thick smear. Blood smear slides were stained with a 10% 
Giemsa solution and examined microscopically under 
oil-immersion at 1000×. Parasitaemia was determined 
by counting the number of asexual parasites against 500 
white blood cells and the density estimated consider-
ing 8000 white blood cells per µl. Slides at day 2 were 
assessed independently by two expert microscopists. A 
third microscopist validated any case of discordance.
Clinical and parasitological responses to treatments 
were classified as follows: (1) parasite negativity rates 
(PNRs) for the proportion of patients without any para-
sitaemia on day 2; (2) parasite positivity rates (PPRs) for 
the proportion of patients remaining parasitaemic on day 
2; and, (3) early treatment failure (ETF) for patients with 
danger signs, complicated malaria or presence of parasi-
taemia on day 2 with fever (rectal temperature ≥38 °C) or 
parasitaemia on day 2 higher than on day 0. Patients were 
excluded from the clinical and parasitological assessment 
if they were lost to follow-up.
Statistical analysis
All statistical tests were performed using GraphPad 
Prism software version 5 (GraphPad Inc., San Diego, 
CA, USA). Data that were not normally distributed were 
displayed as median along with interquartile ranges and 
were compared with Mann–Whitney U test for two 
group comparisons. The Gaussian data were reported as 
the mean ± standard deviation and were analysed using 
the t test for two group comparisons. Proportions were 
compared using the χ2 test or the Fisher’s exact test, as 
appropriate. Correlations were determined using the 
Spearman test. A comparison was considered statistically 
significant if the p value was ≤0.05.
Results
Baseline characteristics of eligible patients through the 
study
Between March and June 2015, a total of 166 patients with 
falciparum malaria were enrolled. The flow of patients 
through the study is displayed in Fig.  1. The baseline 
characteristics of these patients are given in Table 1. The 
weight adjusted drug dose (mg/kg) was calculated in 98% 
of the patients as the body weight was available in 96 of the 
98 patients. Some 76.0% of the patients (73/96) received 
a total dose of DHA and PPQ components, which fol-
lowed WHO recommendations (DHA: 2–10 mg/kg; PPQ: 
16–27  mg/kg). The 24.0% (23/96) other patients who 
received a dose of DHA and PPQ components under the 
WHO recommendations were all over 15 years old.
K13‑propeller polymorphisms
The k13 gene was genotyped from 98 P. falciparum iso-
lates out of the 166 eligible patients. For 57 patients, no 
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Fig. 1 Patients’ flow through the study
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difficulties or technical understaffing and 11 other 
patients used anti-malarial treatment within the 15 day-
period before enrolment (Fig.  1). Five samples failed to 
amplify or did not generate high-quality sequences for 
analysis (Fig.  1). The k13-propeller sequence polymor-
phism analysis of the 93 isolates revealed only wild-type 
profiles (95% CI: 96.31–100%) with four (4.3%) synony-
mous changes.
Ex‑vivo ring‑stage survival assay (RSA)
DHA susceptibility data obtained for the 93 k13-sequenced 
samples were analysed using the ex vivo RSA (Fig. 1). The 
64 isolates with an interpretable RSA (growth rate ≥1) had 
a median survival rate of 0.49% (IQR: 0–1.3) (Fig. 2). Forty 
of the 64 (62.5%) DHA-exposed isolates demonstrated via-
ble parasites with a median parasitaemia of 0.012% (IQR: 
0.007–0.029) and a median survival rate of 1.14% (IQR: 0.6–
2.2) whereas 24 (37.5%) cultures contained only pyknotic/
dead forms (Fig.  2a). The dispersion of ex  vivo RSA data 
was high: four isolates (6.3%) had a survival rate higher than 
the mean survival rate plus 2 standard deviations (3.4%). 
There were no significant differences in the growth rate 
(mean = 1.878 ± 0.435 vs 2.317 ± 0.2413; t-test; P = 0.644) 
or in the initial parasitaemia (mean  =  0.630  ±  0.065 vs 
0.669 ± 0.052; t-test; P = 0.848) between parasites with a 
high or a low survival rate.
Early clinical and parasitological responses to treatment
Clinical and parasitological characteristics of the studied 
population are shown in Table  2. The parasite clearance 
rate for this study was rapid as the PPR decreased to 12.5% 
(8/64) on day 2. The parasitaemia at day 2 in the PPR group 
was low with a median of 293 (IQR: 145–736) and a maxi-
mum of 1143 parasites per µl of blood. No patients pre-
sented ETF. Whereas some isolates remained parasitaemic 
at day 2, the rate of parasite decrease was high and varied 
between 97.5 and 99.9%. The PPR at day 2 was not affected 
by the baseline parasite density at day 0. Most patients 
(92.8%) were totally asymptomatic within 48 h after drug 
administration. No difference in age, weight, fever, DHA/
PPQ anti-malarial doses or symptoms was observed 
between patients in day-2 PPR and PNR groups. No dif-
ference in survival rate in the ex vivo RSA was observed 
between the two groups, day 2 PPR and PNR (Fig. 2b).
Discussion
The spread of resistance threatens the global control of 
falciparum malaria, especially if resistance reaches sub-
Saharan Africa, the most malaria affected area, and this 
makes crucial a closely monitoring of efficacy of ACT.
Here, a genotypic (k13 polymorphism) characteriza-
tion of Cameroonian P. falciparum isolates was reported. 
Ex-vivo and in-vivo phenotypic profiles of these parasites 
were given for comparison in order to have a baseline 
picture of artemisinin susceptibility. The sequencing of 
the k13-propeller domain from samples from Cameroon 
did not reveal resistance genotypes and only detected 
synonymous mutations at a low prevalence (4.3%). The 
genotypic profile observed in this study was consistent 
with other African data that have not reported Asian 
profiles but only non-synonymous SNPs not associated 
with ART resistance [16, 19].
The ex  vivo RSA performed in this study has been 
developed and validated in Southeast Asia to distinguish 
fast-clearance parasites from slow-clearance parasites 
in the field [15], and resistance phenotypes obtained 
in RSA strongly correlate with the presence of muta-
tions in the k13-propeller domain [13]. The phenotypic 
data obtained from this study were in agreement with 
the genotypic ones. The absence of k13 polymorphisms 
was associated with a low median of survival rate for the 
tested isolates (0.49%). The high dispersion of ex  vivo 
RSA data observed in this study could not be explained 
Table 1 Baseline characteristics of  the patients included 




 Sex ratio n (%) 0.96
 Male 48 (49.0%)
 Female 50 (51.0%)
Age
 Median age (IQR) (years) 11.5 (6–18.8)
 <8 years n (%) 39 (39.8%)
 8–15 years n (%) 23 (23.5%)
 >15 years n (%) 36 (36.7%)
Body weight (n = 96)
 Median body weight (IQR) (kg) 33 (21–57)
 <25 kg n (%) 37 (38.5%)
 ≥25 kg n (%) 59 (61.5%)
Temperature
 Median (IQR) (°C) 38.2 (37–39.5)
 Fever (temperature ≥ 38 °C) n (%) 51 (52.0%)
Symptoms n (%)
 Headache 66 (67.3%)
 Vomiting 42 (42.9%)
 Diarrhoea 8 (8.2%)
 Diffuse pain 9 (9.2%)
P. falciparum asexual parasite density
 Median parasitaemia (IQR) (parasites/µl) 42,332 (17,893–87,302)
Anti‑malarial dose (mg/kg) (n = 96)
 DHA Median (IQR) 2.5 (2.0–3.0)
 PPQ Median (IQR) 19.8 (16.3–24)
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by the variability in parasite clearance time as no signifi-
cant difference in survival rates was observed between 
PPR and PNR isolates. Moreover, the four isolates with a 
survival rate higher than the mean plus 2 standard devia-
tions showed no remaining parasitaemia on day 2 and 
had no k13 polymorphism. These results are comparable 
to those observed by Ashley et al. who occasionally found 
patients with parasite clearance half-life values more than 
5 hours but without association with k13 polymorphisms 
[21]. These data were consistent with the survival rates 
obtained in the only ex vivo RSA study performed in East 
Africa (Uganda), which varied between 0.7 and 1.9% [17]. 
However, in their study, Cooper et al. reported only three 
out of 43 DHA-pulsed cultures with healthy-appearing 
parasites [17], which is lower than that obtained in the 
present work (40/64). Other factors unrelated to ART 
resistance could influence the dispersion in survival rate 
and/or a low number of positive DHA-pulsed cultures, 
such as a lower growth rate during the ex vivo RSA or a 
difference in parasite age or density at the initiation of the 
test. Indeed Witkowski et  al. pointed out in Cambodia 
that a growth rate higher than 1 is required to correctly 
analyse survival rate from ex  vivo RSA [15]. Witkowski 
et al. also showed that RSA performed with late-ring or 
trophozoite forms does no longer identify a slow-clear-
ance infection, by contrast to RSA with early-ring forms 
[15]. So storage and transport conditions of parasite iso-
lates before processing are highly important in order to 
have the earliest parasite stages and then to obtain the 
more reliable survival rates in the ex vivo RSA.
In this study, the genotypic and ex  vivo phenotypic 
profiles were associated with a rapid parasite reduc-
tion ratio. At day 2, 87.5% (56/64) of patients had no 
detectable parasitaemia, the remaining 12.5% had a 
low P. falciparum density and the prevalence of clini-
cal symptoms was highly reduced for all patients. Sim-
ple measure of parasitaemia is a good approximation 
of the parasite clearance rate [21]. In this study, the 
clinical and parasitological assessment was chosen to 
be based on a follow-up with two time points, at enrol-
ment (day 0) and at day 2, regarding the fast parasite 





























Fig. 2 Ex‑vivo survival after exposure to DHA. Ex‑vivo RSA exposed 93 isolates obtained from patients with uncomplicated falciparum malaria to 
700 nM DHA or dimethyl sulfoxide (DHA solvent) during 6 h. Data were considered interpretable if the growth rate was ≥1. a Results obtained 
in the ex vivo RSA from the 64 isolates with interpretable data (growth rate was ≥1) are expressed as the survival rate of P. falciparum parasites 
after a 6 hour exposure to 700 nM DHA compared with dimethyl sulfoxide (DHA solvent). The horizontal line represents the mean and whiskers the 
interquartile range. b Survival rates obtained in the ex vivo RSA from the 64 isolates with interpretable data are expressed in the two groups, day 2 
PNR and day 2 PPR. Day 2 PNR represented the proportion of non‑parasitaemic patients on day 2 whereas day PPR 2 represented the proportion of 
patients remaining parasitaemic on day 2, respectively. The ex vivo RSA data were analysed using the t‑test for two group comparisons
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Nkol-Eton healthcare centre. Despite a possible correla-
tion between parasitaemia at day 2/3 and at enrolment 
[26], the assessment of the proportion of patients with 
a detectable parasitaemia at day 2 seemed a relevant 
parameter for quantitatively comparing with genotypic 
and ex vivo phenotypic profiles, and for rapidly detect-
ing any change in P. falciparum susceptibility. Moreover 
this follow-up is easier to implement in healthcare cen-
tres compared to the six measurements within the first 
48 h of treatment that require hospitalization of patients 
and a dedicated staff.
This study finally shows the feasibility of an overall, 
effective and inexpensive assessment of the susceptibil-
ity of P. falciparum to artemisinin derivatives that could 
be implemented in most endemic countries with minimal 
equipment (listed in “Methods” section, with the excep-
tion of sequencing that can be achieved at a later stage) 
but with experienced and well-trained technicians for the 
correct execution of the RSA.
Conclusions
This study gives reassurance about the level of ART 
resistance in Cameroon and provides baseline data of k13 
polymorphism, survival rate in ex vivo RSA and PPR pro-
files that will be essential for monitoring ART-derivative 
susceptibility in Africa. Similar studies will be required in 
other African countries to obtain an exhaustive view of 
these phenotypic data.
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